A systematic review of nerve-sparing surgery for high-risk prostate cancer.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 14 1 2021
medline: 27 7 2021
entrez: 13 1 2021
Statut: ppublish

Résumé

We provide a systematic analysis of nerve-sparing surgery (NSS) to assess and summarize the risks and benefits of NSS in high-risk prostate cancer (PCa). We have undertaken a systematic search of original articles using 3 databases: Medline/PubMed, Scopus, and Web of Science. Original articles in English containing outcomes of nerve-sparing radical prostatectomy (RP) for high-risk PCa were included. The primary outcomes were oncological results: the rate of positive surgical margins and biochemical relapse. The secondary outcomes were functional results: erectile function (EF) and urinary continence. The rate of positive surgical margins differed considerably, from zero to 47%. The majority of authors found no correlation between NSS and a positive surgical margin rate. The rate of biochemical relapse ranged from 9.3% to 61%. Most of the articles lacked data on odds ratio (OR) for positive margin and biochemical relapse. The presented results showed no effect of nerve sparing (NS) on positive margin (OR=0.81, 0.6-1.09) or biochemical relapse (hazard ratio [HR]=0.93, 0.52-1.64). A strong association between NSS and potency rate was observed. Without NSS, between 0% and 42% of patients were potent, with unilateral 79-80%, with bilateral - up to 90-100%. Urinary continence was not strongly associated with NSS and was relatively good in both patients with and without NSS. NSS may provide benefits for patients with urinary continence and significantly improves EF in high-risk patients. Moreover, it is not associated with an increased risk of relapse in short- and middle-term follow-up. However, the advantages of using such a surgical technique are unclear.

Identifiants

pubmed: 33439578
pii: S0393-2249.20.04178-8
doi: 10.23736/S2724-6051.20.04178-8
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-291

Auteurs

Andrey Morozov (A)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Eric Barret (E)

Department of Urology, Institute Mutualiste Montsouris, Paris, France.

Domenico Veneziano (D)

Department of Urology and Kidney Transplant, G.O.M. Reggio Calabria, Reggio Calabria, Italy.
Hofstra University, New York, NY, USA.

Vagarshak Grigoryan (V)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Georg Salomon (G)

Martini Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Igor Fokin (I)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Mark Taratkin (M)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia - marktaratkin@gmail.com.
European Association of Urology (EAU), Arnhem, the Netherlands.

Elena Poddubskaya (E)

Sechenov University, Moscow, Russia.

Juan Gomez Rivas (J)

Department of Urology, La Paz University Hospital, Madrid, Spain.

Stefano Puliatti (S)

Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Zhamshid Okhunov (Z)

Department of Urology, University of California, Irvine, CA, USA.

Giovanni E Cacciamani (GE)

Keck School of Medicine, Department of Urology, Catherine & Joseph Aresty Foundation, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Department of Radiology, University of Southern California, Los Angeles, CA, USA.

Enrico Checcucci (E)

School of Medicine, Division of Urology, Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy.

José L Marenco Jiménez (JL)

Virgen Macarena University Hospital, Seville, Spain.

Dmitry Enikeev (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Section of Urotechnology, European Association of Urology (EAU), Arnhem, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH